Featured Press Release

  • Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference
    5/15/19 4:30 pm EDT
    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 RBC Capital Markets Global Healthcare Conference as follows: Date:     Wednesday, May 22, 2019See More
  • Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results
    5/7/19 6:50 am EDT

    -- Q1 2019 net income of $0.64 per basic and $0.62 per diluted share and adjusted non-GAAP net income of $1.05 per basic and $1.01 per diluted share --

    -- Revised licensing agreement for BENDEKA® extends term of contract and increases royalty rate to 32% in 2021 --

    -- CMS issues unique J-code for BELRAPZO™ (500mL infusion bendamustine solution) –

    -- Announced statistically significant neuroprotective effects of RYANODEX® in a well-established nerve agent model --

    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced its financial results for the three months ended March 31, 2019. Highlights of, and subsequent to, the first quarter of 2019 include: Business and Recent Highlights: Completed a successful study to evaluate the neuroprotective effects of RYANODEX® (dantrolene sodium) for the treatment of nerveSee More
  • Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure
    5/7/19 6:45 am EDT

    -- Statistically significant lower incidence of brain damage compared to control group, demonstrating neuroprotective properties of RYANODEX in treating nerve agent exposure --

    -- Statistically significant robust p-values of 0.04 or less were determined in six cortical areas of the brain --

    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced positive results of its study to evaluate the neuroprotective effects of RYANODEX® (dantrolene sodium) secondary to nerve agent (NA) exposure, conducted with the United States Army Medical Research Institute of Chemical Defense (USAMRICD), the nation's leading science and technology laboratory in the area of medical chemicalSee More

Featured Presentation

Business Wire InvestorHQsm